

**A Novel Off-The-Shelf (OTS) Endograft For All Aortic Arch Pathologies: What Makes It Unique And Promising: Early Clinical Results**



**Wayne W. Zhang, MD, FACS, DFSVS**

Distinguished Professor and Director  
Cardiovascular Research Lab  
Chinese Institutes for Medical Research  
And Beijing Anzhen Hospital  
Capital Medial University






**Disclosure**



Inventor of the ZIPPER™ endograft system  
Consultant: LifeTech Scientific  
Consultant: EndoNom Medtech  
Consultant: MicroPort Medical



**Key Features**

- Pre-shaped and steerable delivery system
- Pre-wired innominate artery (IA)
  - 30-degree wire angle separation from the constrained proximal main-body stent-graft
  - Avoid wire wrapping and easy for snaring
- Outer/inner convertible IA branch
- Constrained proximal main-body stent-graft
- Proximal end capture release mechanism
- Funnel-shaped LCCA and LSA graft orifices facilitating branch selection
- **Off-the-Shelf**, suitable for majority of the patients' arch anatomy



**Publication**

**JOURNAL ARTICLE**

**First-in-man ZIPPER™ endograft system for the treatment of symptomatic aortic arch intramural haematoma**

Honglin Dong, Weiguo Fu, Wayne W Zhang

European Heart Journal - Case Reports, Volume Issue 11, November 2023, ytad574, <https://doi.org/10.1093/ehjcr/ytad574>

Published: 17 November 2023



**FRANK J. VEITH International Society**

FOURTH ANNUAL INNOVATION IN VASCULAR SURGERY & ENDOVASCULAR THERAPY AWARDS

Friday, October 4, 2024 12:00 PM - 1:30 PM EST

Complimentary Registration [CLICK HERE TO REGISTER](#)

**INTRODUCTION**  
Boris Wenzel, MD  
Director, Vascular, Endovascular, and Thoracic Medicine, Yale

**MODERATOR**  
Pradyumn K. Sanyal, MD  
Professor of Vascular Medicine, Yale

**AWARD WINNERS**


**Young to Middle Age Group**  
Pradyumn K. Sanyal, MD  
Professor of Vascular Medicine, Yale

**Older to Middle Age Group**  
Boris Wenzel, MD  
Director, Vascular, Endovascular, and Thoracic Medicine, Yale

**FIH (n=18): 30-day Perioperative Outcomes**

- Types of aortic arch pathologies
  - Non-A non-B AD: 10 (55.56%)
  - TAAD s/p open Bentall: 4 (22.22%)
  - Aneurysm: 3 (16.67%)
  - TAAO: 1 (5.55%)
- Technical success: 100%**
  - Total percutaneous transfemoral repair in the last 13 consecutive patients
- Stentgraft patency: 100%**
- Endo re-intervention: 5.56%**
- Perioperative Death: 0.00%**
- Major Stroke: 0.00%**
  - 1 developed right hand fine motor dysfunction, recovered in 1 month
- Endoleaks: 17.64% (3/17)**
  - 17/18 patients had 30-day f/u CTA\*
  - Type III: 1/17 (5.88%)
  - Type II: 2/17 (11.76%)
- Retrograde AD: 11.11% (2/18)**
  - 1 SINE, converted to open repair: 1/18 (5.56%)
  - The other patient is refusing open surgery
- Access complications: 1/18 (5.56%)**
  - Brachial artery pseudoaneurysm

\* 17/18 patients had 30-day follow-up CTA up to now. AD: aortic dissection; SINE: Stentgraft-induced new entry



A novel off-the-shelf stentgraft device  
for total transfemoral endovascular  
treatment of aortic arch dissection

